转化医学杂志2024，Vol.13Issue(11)：2026-2029,4.DOI:10.3639/j.issn.2095-3097.2024.11.051
评估多重耐药铜绿假单胞菌的共耐药率和患者预后研究
Evaluation of Co-Resistance Rate and Patient Prognosis of Multi-Drug Resistant Pseudomonas Aeruginosa
摘要
Abstract
Objective To analyze the co-resistance rate of multi-drug resistant(MDR)Pseudomonas aeruginosa infec-tion and its impact on patient prognosis.Methods The clinical data of 180 patients hospitalized due to MDR Pseudomonas aeruginosa infection in Xiangshui People's Hospital of Jiangsu Province from January 2021 to December 2023 were collected.The co-resistance rate of multi-drug resistant Pseudomonas aeruginosa and patient prognosis were retrospectively analyzed.Results Stratified by common co-resistance patterns,there was a significant difference in the in-hospital mortality rate of patients infected with MDR Pseudomonas aeruginosa strains between the co-resistance of non-carbapenems(CARB),.extend-ed-spectrum cephalosporins(ESC)and piperacillin-tazobactam(PT)and CARB,ESC and PT(P<0.0001,OR=5.14),but there was no significant difference in readmission due to reinfection within one year after discharge(P>0.05,OR=0.91).The index isolates of MDR Pseudomonas aeruginosa had a high individual resistance rate to commonly used antibiotics,and a high com-bined resistance rate of resistance to CARB and ESC plus resistance to PT or fluoroquinolones(FQ).When ceftolozane-tazobac-tam(CT)and ceftazidime-avibactam(CA)were added to the co-resistance patterns of CARB/ESC/PT and CARB/ESC/FQ,the lowest co-resistance rate was observed.Conclusion The co-resistance rate of multi-drug resistant Pseudomonas aeruginosa is relatively high.The co-resistance pattern of CARB,ESC and PT is positively correlated with patient prognosis.Combined therapy has certain advantages over single-drug therapy.关键词
多重耐药铜绿假单胞菌/共耐药率/患者预后/联合治疗Key words
Multi-drug Resistant Pseudomonas Aeruginosa/Co-resistance Rate/Patient Prognosis/Combined Therapy分类
医药卫生引用本文复制引用
李玉巧,张子书..评估多重耐药铜绿假单胞菌的共耐药率和患者预后研究[J].转化医学杂志,2024,13(11):2026-2029,4.基金项目
江苏省卫生健康委科研项目(H2020135) （H2020135）
